Abstract
Introduction
Anaemia has a high worldwide prevalence, and is estimated to affect 1. 6 Anaemia can cause fatigue and decreased work activity. (2) It has been shown to worsen heart failure (3) and is associated in increased mortality in people with chronic heart failure. (4) Anaemia is also associated with worse outcomes after cardiac and non-cardiac surgery, including increased mortality and hospital length of stay. (5, 6) Approximately 50% of anaemia is due to iron deficiency.(1, 7, 8) Absolute iron deficiency can be caused by nutritional deficiency of iron, loss due to bleeding or decreased absorption of dietary iron, causing a lack of stored iron. Alternatively, a state of functional iron deficiency can occur, leading to iron restricted erythropoiesis despite normal iron stores. Functional iron deficiency can be caused by: defective incorporation of iron into developing red cells, decreased availability of iron stores as the result of increased uptake and retention of iron within the reticuloendothelial system or failure of absorption of intestinal iron due to inflammation, mediated by hepcidin. Chronic inflammation and disease may lead to increased hepcidin levels and thus anaemia of chronic disease. (9) European Society of Cardiology guidelines recommend the diagnosis and treatment of correctable causes of anaemia in heart failure. 
Methods
The Cochrane methodology was applied to this review.(11) Table 1 presents the inclusion and exclusion criteria of studies. (13) all known relevant electronic databases and search engines were accessed. and routes, were eligible to be included in the meta-analysis. RCTs irrespective of blinding, language, publication status and date of publication, study setting and sample size were included. Any non-peripartum anaemic adults without chronic kidney disease were included in this review, irrespective of the setting and the degree of anaemia. The primary outcome of interest was mortality at one year.
As per the Cochrane Handbook for Systematic Reviews of Interventions
Risk of bias was assessed as per the instructions of the Cochrane Handbook (13) according to the following domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting and source of funding bias.
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Two review authors (KSG and TR or BC) identified trials for inclusion independently of each other, listing excluded studies and the reason for exclusion. Differences were resolved by discussion.
Statistical Analysis
Meta-analyses were performed using the software package Review Manager version 5.3(18) and in accordance with the recommendations of the Cochrane Handbook. (13) The results of the random effects model were reported. The risk ratio (RR) with 95% confidence interval (CI) was calculated for dichotomous variables, and the mean difference (MD) with 95% CI or standardised mean difference (SMD) with 95% CI as appropriate for continuous variables. For timeto-event outcomes such as mortality at maximal follow-up, hazard ratio (HR) with 95% CI was calculated.
Subgroup analyses were performed for trials studying participants chronic heart failure compared to those without. Subgroup analyses were also performed in trials in which erythropoietin was used as a co-intervention versus those that did not, and by participant group: blood loss conditions, cancer, pre-operative, autoimmune and miscellaneous (See supplementary online appendix for these results). Test for subgroup differences within Review Manager was used, with a P value of <0.05 considered statistically significant. 
Results

Study selection
Overall, 225 full text publications from 17693 citations were identified as potentially relevant studies and full text copies were retrieved and assessed.
Exclusions are detailed in 
Results
Mortality
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The primary outcome of interest was mortality at one year. However, only one trial reported mortality at one year,(20) (in which the mortality in both oral iron and no iron group was 29% (p=1)) therefore hazard ratio was not calculated for any of the comparisons. 
4)
Proportion requiring blood transfusion
Comparing oral iron vs. inactive control, (19, 21, 62, 64, 66) 
Length of hospital stay
One study compared length of hospital stay for oral iron vs. inactive control, (20) whilst one trial compared length of hospital stay for parenteral versus oral iron;(47) neither showed any significant difference.
Subgroup Analysis -Chronic Heart Failure
Only one study included comparison of oral to parenteral iron, and oral iron to inactive control in heart failure, reporting mortality and haemoglobin concentration.(63) Subgroup analysis of oral to parenteral iron in patients with heart failure versus those without revealed no significant subgroup differences in mortality (p=0.44) or haemoglobin (p=0.59). When comparing oral iron to inactive control in patients with and without heart failure there was no significant difference in mortality (p=0.39) and haemoglobin concentration (p=0.93) between the groups.
Comparing parenteral iron to inactive control in patients with and without heart failure showed no significant difference in mortality (p=0.79), haemoglobin Iron for Anaemic Adults 12 (p=0.99), quality of life (p=0.95) or serious adverse events (p=0.14) between these groups.
In patients with heart failure the point estimate haemoglobin concentration was significantly higher in patients given intravenous iron compared to placebo (MD 1.12 (95%CI 0.11 to 2.14), yet without any significant difference in mortality, quality of life or serious adverse events.
Heterogeneity
The heterogeneity within the studies ranged from low (for mortality, I 2 =0, and serious adverse events, to considerable for haemoglobin (I 2 =67% for oral iron vs.
inactive control, I 2 =93% for parenteral iron vs. inactive control and I 2 =41% for parenteral vs. oral iron.
Discussion
This systematic review reviewed the utility of iron therapy for the treatment of anaemia in non-peripartum anaemic adults without chronic kidney disease. Most of the trials included patients with mild to moderate anaemia. The trials did not demonstrate clinical benefit in terms of mortality. In all comparisons there were no significant subgroup differences in the results comparing patients with and without heart failure.
Both oral and parenteral iron led to higher level of haemoglobin compared to inactive controls, and parenteral iron demonstrated a statistically significant rise in comparison to oral iron.
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Parenteral iron demonstrated a statistically significant benefit in quality of life when compared to inactive control but no significant difference when compared to oral iron. It was not possible to estimate the clinical importance of this difference. The only trial comparing oral iron to inactive control showed no statistically significant difference. (66) Both oral iron and parenteral iron demonstrated a significant reduction in the risk of blood transfusion when compared to inactive control, with no significant difference between the two modes of administration when compared to one another.
There was no significant difference in the proportion of patients who developed serious adverse events as a result of parenteral or oral iron therapy. Most trials reporting serious adverse events reported that there were no allergic or anaphylactic reactions or serious reactions, suggesting that these are rare.
Parenteral iron was demonstrated to result in increased haemoglobin levels and a reduction in blood transfusion when compared to inactive controls, without any statistically significant increase in adverse events. However, no improvement in quality of life or mortality was demonstrated in these studies.
Most of the adverse events related to oral iron therapy were gastrointestinal side effects such as nausea, diarrhoea or constipation. While the balance of the benefits and harms of oral iron therapy appear to favour routine oral iron therapy in anaemic patients, the quality of evidence is very low. There were no significant clinical benefits of one iron preparation or regimen over another.
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Thus, there is little evidence on to recommend one preparation or regimen over another.
Subgroup analyses were performed to determine whether iron would be useful in specific clinical situations or whether iron therapy might be useful in patients who are receiving erythropoietin. The results were not consistent enough to enable us determine this. In anaemic patients with heart failure, iron improved the haemoglobin concentration without any improvement in other clinically relevant endpoints.
This analysis is applicable only in non-peripartum anaemic adults without chronic kidney disease with mild to moderate anaemia. It should also be noted that most trials excluded patients who were allergic to iron therapy and measured the ferritin and transferrin levels to ensure that the patients had iron deficiency anaemia.
None of the trials were of a low risk of bias in every domain assessed. Many trials did not report important clinical outcomes, although it is likely that such clinical outcomes were measured. This has resulted in significant selective outcome reporting bias. We did found evidence of publication bias in haemoglobin levels and we found evidence of selective reporting, i.e. many clinical trials reported haemoglobin levels but not clinical outcomes. We imputed the mean and standard deviation when these were not available. This could have introduced bias. However, there was no evidence of such a bias when exclusion of trials with imputed data did not alter the results significantly.
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The previous systematic review of iron in non-pregnant and non-lactating anaemic adults without chronic kidney disease failed to show any clinical benefit of intravenous iron compared to oral iron or inactive controls beyond improving haemoglobin levels.(11) This expanded meta-analysis showed a statistical difference in blood transfusion rates and quality of life for parenteral iron when compared to inactive control. However, the clinical significance of this is not known, particularly since there was no difference in mortality rates. There is a growing recognition that anaemia is a significant comorbidity in patients that may not be modifiable, whether by iron replacement, or blood transfusion. In heart failure, treatment of iron deficiency itself may be more important than anaemia per se.
The recognition of functional iron deficiency modulated by hepcidin, and its associate with inflammation provides an explanation for the efficacy of parenteral iron when compared to oral iron in producing a rise in haemoglobin in anaemic patients. In spite of demonstrating a greater haemoglobin response than oral iron, parenteral iron failed to show any other benefits over oral preparations.
In the context of heart failure with or without anaemia, intravenous iron has been shown to reduce readmission to hospital, (84) and to improve renal function.(85) Iron replacement is recommended for all iron deficient patients with heart failure, regardless of whether they are anaemic. The majority of patients with heart failure receive oral iron, despite evidence lacking for its benefit in these patients.(86) Only one trial comparing oral versus intravenous iron in anaemic patient with heart failure was included in this systematic Iron for Anaemic Adults 16 review, (63) and further trials are required comparing oral to intravenous iron in anaemic patients with heart failure.
Recently, a systematic review was published which included all trials in which intravenous iron was compared with either oral iron or no iron therapy irrespective of the clinical setting.(87) Our findings are broadly similar to that review which found that intravenous iron increased haemoglobin levels and decreased transfusion requirements. However, that systematic review found infective complications higher with intravenous iron. In this review, there were no significant differences in the serious adverse events. However, the confidence intervals were wide and so the observation is our systematic review might have been due to lack of evidence of effect rather than lack of effect.
In conclusion, intravenous iron is effective in improving haemoglobin levels compared to oral iron or inactive controls. Oral iron improves haemoglobin levels in comparison to inactive control. Neither reduced mortality, however both reduced blood transfusion rates, and parenteral iron demonstrated statistically significant improvement in quality of life, although the clinical significance of this increase is not known. The analysis of trials of heart failure patients within this study showed the same outcomes. From these findings, more randomised controlled trials at a low risk of bias, powered to measure clinically useful endpoints including mortality, blood transfusion and quality of life are still required in all patient populations, including those with heart failure.
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